CGP-37849 is a competitive antagonist at the NMDA receptor. Fagg GE, Olpe HR, Pozza MF, Baud J, Steinmann M, Schmutz M, Portet C, Baumann P, Thedinga K, Bittiger H, et al. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. British Journal of Pharmacology. 1990 Apr;99(4):791-7. It is a potent, orally active anticonvulsant in animal models, Schmutz M, Portet C, Jeker A, Klebs K, Vassout A, Allgeier H, Heckendorn R, Fagg GE, Olpe HR, van Riezen H. The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn-Schmiedebergs Archives of Pharmacology. 1990 Jul;342(1):61-6. and was researched for the treatment of epilepsy. Fujikawa DG, Daniels AH, Kim JS. The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage. Epilepsy Research. 1994 Mar;17(3):207-19. It also has neuroprotective activityGutnikov SA, Gaffan D. Systemic NMDA receptor antagonist CGP-40116 does not impair memory acquisition but protects against NMDA neurotoxicity in rhesus monkeys. Journal of Neuroscience. 1996 Jun 15;16(12):4041-5. and shows antidepressantMaj J, Klimek V, Gołembiowska K, Rogóz Z, Skuza G. Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity. Polish Journal of Pharmacology. 1993 Sep-Dec;45(5-6):455-66. Papp M, Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. European Journal of Pharmacology. 1994 Sep 22;263(1-2):1-7. and anxiolytic effects.Jessa M, Nazar M, Bidzinski A, Plaznik A. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. European Neuropsychopharmacology. 1996 Mar;6(1):55-61. Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology. 2000 Jul 24;39(10):1858-64 .
CGP-37849 is a competitive antagonist at the NMDA receptor. It is a potent, orally active anticonvulsant in animal models, and was researched for the treatment of epilepsy. It also has neuroprotective activity and shows antidepressant and anxiolytic effects .
D
Fagg GE, Olpe HR, Pozza MF, Baud J, Steinmann M, Schmutz M, Portet C, Baumann P, Thedinga K, Bittiger H, et al. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. British Journal of Pharmacology. 1990 Apr;99(4):791-7.
R
Schmutz M, Portet C, Jeker A, Klebs K, Vassout A, Allgeier H, Heckendorn R, Fagg GE, Olpe HR, van Riezen H. The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn-Schmiedebergs Archives of Pharmacology. 1990 Jul;342(1):61-6. and
and
D
Fujikawa DG, Daniels AH, Kim JS. The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage. Epilepsy Research. 1994 Mar;17(3):207-19.
R
activityGutnikov SA, Gaffan D. Systemic NMDA receptor antagonist CGP-40116 does not impair memory acquisition but protects against NMDA neurotoxicity in rhesus monkeys. Journal of Neuroscience. 1996 Jun 15;16(12):4041-5. and shows antidepressantMaj J, Klimek V, Gołembiowska K, Rogóz Z, Skuza G. Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity. Polish Journal of Pharmacology. 1993 Sep-Dec;45(5-6):455-66. Papp M, Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. European Journal of Pharmacology. 1994 Sep 22;263(1-2):1-7. and anxiolytic effects.Jessa M, Nazar M, Bidzinski A, Plaznik A. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. European Neuropsychopharmacology. 1996 Mar;6(1):55-61. Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology. 2000 Jul 24;39(10):1858-64
activity and shows antidepressant and anxiolytic effects